Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05971693
Other study ID # BWI202201
Secondary ID BWI202201
Status Recruiting
Phase N/A
First received
Last updated
Start date September 12, 2023
Est. completion date April 30, 2025

Study information

Verified date June 2024
Source Biosense Webster, Inc.
Contact Study Contact
Phone +32 479 97 05 05
Email nmacours1@its.jnj.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to demonstrate safety and effectiveness of the ablation system (OMNYPULSE Bi-directional catheter and TRUPULSE generator) when used for isolation of the atrial pulmonary veins (PVs) in treatment of participants with paroxysmal atrial fibrillation (PAF).


Recruitment information / eligibility

Status Recruiting
Enrollment 160
Est. completion date April 30, 2025
Est. primary completion date April 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Diagnosed with Symptomatic paroxysmal atrial fibrillation (PAF) defined as as atrial fibrillation (AF) that terminates spontaneously or with intervention within 7 days of onset. This PAF is considered to be symptomatic if symptoms related to AF are experienced by the participant - Selected for AF ablation procedure by pulmonary vein isolation (PVI) - Willing and capable of providing consent - Able and willing to comply with all pre-, post- and follow-up testing and requirements Exclusion Criteria: - Previously known AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause (example, documented obstructive sleep apnea, acute alcohol toxicity, morbid obesity [body mass index greater than {>} 40 kilograms per meter square {kg/m^2}]), renal insufficiency (with an estimated creatinine clearance less than (<) 30 milliliters per minute per 1.73 meter square [mL/min/1.73 m^2]) - Previous left atrium (LA) ablation or surgery - Participants known to require ablation outside the PV region (example, atrioventricular reentrant tachycardia, atrioventricular nodal re-entry tachycardia, atrial tachycardia, ventricular tachycardia and Wolff-Parkinson-White) - Previously diagnosed with persistent AF (> 7 days in duration) - Severe dilatation of the left atrium (LA) (left anterior descending artery [LAD] >50 millimeter [mm] antero-posterior diameter in case of transthoracic echocardiography [TTE]) - Presence of LA thrombus - Severely compromised left ventricular ejection fraction (left ventricular ejection fraction [LVEF] <40 percentage [%]) - Uncontrolled heart failure or New York Heart Association (NYHA) Class III or IV - History of blood clotting, bleeding abnormalities or contraindication to anticoagulation (heparin, warfarin, or dabigatran) - History of a documented thromboembolic event (including transient ischemic attack [TIA]) within the past 6 months - Previous percutaneous coronary intervention (PCI) / myocardial infarction (MI) within the past 2 months - Previous coronary artery bypass grafting (CABG) in conjunction with valvular surgery, cardiac surgery (example, ventriculotomy, atriotomy) or valvular cardiac (surgical or percutaneous) procedure - Unstable angina pectoris within the past 6 months - Anticipated cardiac transplantation, cardiac surgery, or other major surgery within the next 12 months - Significant pulmonary disease (example, restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other disease or malfunction of the lungs or respiratory system that produces severe chronic symptoms - Known significant pulmonary vein (PV) anomaly that in the opinion of the investigator would preclude enrollment in this study - Prior diagnosis of pulmonary vein stenosis - Pre-existing hemi diaphragmatic paralysis - Acute illness, active systemic infection, or sepsis - Presence of intracardiac thrombus, myxoma, tumor, interatrial baffle or patch or other abnormality that precludes catheter introduction or manipulation - Severe mitral regurgitation - Presence of implanted pacemaker or implantable cardioverter-defibrillator (ICD) or other implanted metal cardiac device that may interfere with the pulsed electric field energy - Presence of a condition that precludes vascular access (such as Inferior Vena Cava [IVC] filter) - Significant congenital anomaly or a medical problem that in the opinion of the investigator would preclude enrollment in this study - Categorized as vulnerable population and requires special treatment with respect to safeguards of well-being - Current enrollment in an investigational study evaluating another device or drug - Women who are pregnant (as evidenced by pregnancy test if pre-menopausal), lactating, or who are of child-bearing age and plan on becoming pregnant during the course of the clinical investigation - Life expectancy less than 12 months - Presenting contra-indications for the devices used in the study, as indicated in the respective Instructions For Use (IFU) - Known contraindication for magnetic resonance imaging (MRI) such as use of contrast agents due to advanced renal disease, claustrophobia etcetra. (at principle investigator [PI] discretion) - Presence of iron-containing metal fragments in the body - Known unresolved pre-existing neurological deficit - Known uncontrolled significant gastroesophageal reflux disease (GERD)

Study Design


Related Conditions & MeSH terms


Intervention

Device:
OMNYPULSE Bi-Directional Catheter with TRUPULSE Generator
Participants will undergo catheter ablation with the PF ablation system consisting of the TRUPULSE generator (delivers PF energy through the study catheter) and the OMNYPULSE bi-directional catheter (indicated for use in catheter-based cardiac electrophysiological mapping [stimulating and recording] and, when used with a Generator, for cardiac ablation).

Locations

Country Name City State
Belgium O L V Ziekenhuis Aalst
Belgium AZ Sint-Jan Brugge
Belgium Ziekenhuis Oost-Limburg Genk
Belgium Jessa Ziekenhuis - Campus Virga Jesse Hasselt
Canada McGill University Health Centre Montreal Quebec
Canada Montreal Heart Institute Montreal Quebec
Croatia KBC Split Split
Czechia IKEM Prague
Czechia Nemocnice na Homolce Prague
Germany MVZ CCB Frankfurt und Main Taunus GbR Frankfurt a.M.
Italy Generale Regionale F. Miulli Acquaviva delle Fonti
Lithuania Vilnius University Hospital Santariskiu Klinikos Vilnius
Netherlands Maastricht UMC Maastricht

Sponsors (1)

Lead Sponsor Collaborator
Biosense Webster, Inc.

Countries where clinical trial is conducted

Belgium,  Canada,  Croatia,  Czechia,  Germany,  Italy,  Lithuania,  Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants with Primary Adverse Events (PAE's) Number of Participants with incidence of PAEs (within 7 days following the ablation procedure) will be reported. PAE's will include the following adverse events atrio-esophageal fistula, phrenic nerve paralysis, cardiac tamponade/perforation, pulmonary vein stenosis, device or procedure related death, stroke/cerebrovascular accident (CVA), major vascular access complication/bleeding, thromboembolism, myocardial infarction, transient ischemic attack (TIA), pericarditis, heart block, pulmonary edema (respiratory insufficiency) and vagal nerve injury/gastroparesis. 7 days post-ablation procedure on Day 0 (up to Day 7)
Primary Percentage of Participants with Acute Effectiveness Percentage of participants with acute effectiveness will be reported. Acute effectiveness is an electrical isolation of clinically relevant targeted pulmonary veins (PVs) (confirmed by entrance block) after adenosine/isoproterenol challenge at the end of the index ablation procedure. Use of a non-study device to achieve PV isolation is considered an acute procedural failure. Immediate post-procedure
Secondary 12-month Effectiveness: Number of Participants who Achieved Freedom from Documented Atrial Arrhythmia Episodes During the Effectiveness Evaluation period (AF, AT or AFL of Unknown Origin) within Day 91 to Day 365 Post Index Procedure 12-month effectiveness: Number of participants rate of Freedom from documented (symptomatic and asymptomatic) Atrial Arrhythmia (Atrial Fibrillation [AF], Atrial Tachycardia [AT] or Atrial Flutter [AFL] of unknown origin) episodes assessed during the effectiveness evaluation period (Day 91 to Day 365 days post index procedure will be reported. Freedom from atrial arrhythmia will be reported based on electrocardiographic data (greater than or equal to [>=30] seconds on arrhythmia monitoring device) during the effectiveness evaluation period on or off antiarrhythmic therapy. Acute procedural failure (that is, failure to achieve entrance block with the study device in any of the clinically relevant targeted PVs) will also be deemed a 12- month effectiveness failure. Within Day 91 to Day 365 post-ablation procedure (on Day 1)
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Completed NCT04571385 - A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF) Phase 2
Terminated NCT04115735 - His Bundle Recording From Subclavian Vein
Completed NCT05366803 - Women's Health Initiative Silent Atrial Fibrillation Recording Study N/A
Completed NCT02864758 - Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
Recruiting NCT05442203 - Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease N/A
Completed NCT05599308 - Evaluation of Blood Pressure Monitor With AFib Screening Feature N/A
Completed NCT03790917 - Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
Enrolling by invitation NCT05890274 - Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO N/A
Recruiting NCT05266144 - Atrial Fibrillation Patients Treated With Catheter Ablation
Recruiting NCT05316870 - Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation N/A
Not yet recruiting NCT06023784 - The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Recruiting NCT04092985 - Smart Watch iECG for the Detection of Cardiac Arrhythmias
Completed NCT04087122 - Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures N/A
Completed NCT06283654 - Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
Recruiting NCT05416086 - iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)
Completed NCT04546763 - Study Watch AF Detection At Home
Completed NCT03761394 - Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke N/A